
|Articles|February 7, 2015
Dr. Gary Novack: State of glaucoma pharmaceuticals, what future holds
Gary D. Novack, PhD, president of PharmaLogic Development, co-moderated an industry panel discussion on glaucoma pharmaceuticals Friday during Glaucoma 360. Watch Dr. Novack outline the state of glaucoma drug therapy and where the future is headed.
Advertisement
Gary D. Novack, PhD, president of PharmaLogic Development, co-moderated an industry panel discussion on glaucoma pharmaceuticals Friday during the 4th Annual Glaucoma 360 New Horizons Forum. Watch as Dr. Novack outlines the state of glaucoma drug therapy and where the future is headed.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Ocugen releases positive preliminary 12-month data from phase 2 ArMaDa trial
3
PRIMA retinal implant restores vision in patients with advanced GA
4
Ocugen publishes phase 1 GARDian1 gene therapy data for Stargardt disease
5














































